Mount Yale Investment Advisors LLC Has $821,000 Position in GSK plc (NYSE:GSK)

Mount Yale Investment Advisors LLC boosted its holdings in GSK plc (NYSE:GSK) by 51.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 19,154 shares of the pharmaceutical company’s stock after buying an additional 6,481 shares during the period. Mount Yale Investment Advisors LLC’s holdings in GSK were worth $821,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the company. 1832 Asset Management L.P. raised its holdings in GSK by 9.1% in the first quarter. 1832 Asset Management L.P. now owns 3,078 shares of the pharmaceutical company’s stock worth $132,000 after purchasing an additional 257 shares during the period. Personal CFO Solutions LLC raised its holdings in GSK by 2.7% in the fourth quarter. Personal CFO Solutions LLC now owns 10,087 shares of the pharmaceutical company’s stock worth $374,000 after purchasing an additional 263 shares during the period. J.W. Cole Advisors Inc. raised its holdings in GSK by 4.7% in the first quarter. J.W. Cole Advisors Inc. now owns 6,097 shares of the pharmaceutical company’s stock worth $261,000 after purchasing an additional 271 shares during the period. Chapin Davis Inc. raised its holdings in GSK by 2.2% in the first quarter. Chapin Davis Inc. now owns 14,231 shares of the pharmaceutical company’s stock worth $610,000 after purchasing an additional 300 shares during the period. Finally, Dorsey & Whitney Trust CO LLC raised its holdings in GSK by 2.9% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 10,986 shares of the pharmaceutical company’s stock worth $407,000 after purchasing an additional 306 shares during the period. 15.74% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. The Goldman Sachs Group assumed coverage on shares of GSK in a report on Thursday, May 30th. They set a “neutral” rating and a $47.00 price objective on the stock. UBS Group lowered shares of GSK from a “buy” rating to a “neutral” rating in a report on Monday, July 8th. Jefferies Financial Group raised their price objective on shares of GSK from $52.50 to $53.00 and gave the stock a “buy” rating in a report on Tuesday, July 2nd. Berenberg Bank upgraded shares of GSK to a “strong-buy” rating in a report on Thursday, June 20th. Finally, Citigroup upgraded shares of GSK to a “strong-buy” rating in a report on Monday, June 24th. Three analysts have rated the stock with a hold rating, two have assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $50.00.

GSK Stock Performance

Shares of GSK traded down $0.15 during midday trading on Tuesday, reaching $39.86. The stock had a trading volume of 499,132 shares, compared to its average volume of 3,494,399. The firm has a 50 day simple moving average of $40.69 and a 200-day simple moving average of $41.42. GSK plc has a one year low of $33.67 and a one year high of $45.92. The firm has a market cap of $82.61 billion, a PE ratio of 14.50, a P/E/G ratio of 1.37 and a beta of 0.64. The company has a current ratio of 0.87, a quick ratio of 0.58 and a debt-to-equity ratio of 1.15.

GSK (NYSE:GSK) last announced its quarterly earnings data on Wednesday, May 1st. The pharmaceutical company reported $1.09 EPS for the quarter, beating analysts’ consensus estimates of $0.94 by $0.15. GSK had a net margin of 14.62% and a return on equity of 51.54%. The company had revenue of $9.34 billion during the quarter, compared to the consensus estimate of $8.98 billion. As a group, sell-side analysts anticipate that GSK plc will post 4.1 EPS for the current year.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, July 11th. Investors of record on Friday, May 17th were issued a dividend of $0.3762 per share. This is an increase from GSK’s previous quarterly dividend of $0.36. The ex-dividend date was Thursday, May 16th. This represents a $1.50 annualized dividend and a dividend yield of 3.78%. GSK’s payout ratio is presently 54.71%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.